Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions.
Georges MjaessLaura HaddadTeddy JabbourArthur BaudewynsHenri-Alexandre BourgenoYolène LefebvreMaria Consiglia FerrieroGiuseppe SimoneAlexandre FourcadeGeorges FournierMarco OderdaPaolo GonteroAdrian Bernal-GomezAlessandro MastrorosaJean-Baptiste RocheRawad Abou ZahrGuillaume PloussardGaelle FiardAdam HalinskiKaterina RysankovaCharles DarianeGina DelavarJulien AnractNicolas Barry DelongchampsAlexandre Patrick BuiFayek TahaOlivier Laurent WindischDaniel BenamranGregoire AssenmacherJan BenijtsKarsten GuenzelThierry RoumeguereAlexandre PeltierRomain DiamandPublished in: Prostate cancer and prostatic diseases (2024)
For individuals with PI-RADS 3 lesions on prostate mpMRI and a PSAd below 0.13, especially below 0.09, prostate biopsy can be omitted, in order to avoid unnecessary biopsy and overdiagnosis of non-csPCa.